Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • ADC Linker
    (1)
  • Antibody-Drug Conjugates (ADCs)
    (1)
  • PROTAC Linker
    (1)
TargetMol | Tags By Application
  • ELISA
    (1)
  • FCM
    (1)
  • Functional assay
    (1)
TargetMol | Tags By ResearchField
  • Cancer
    (2)
  • Immune System
    (1)
  • Inflammation
    (1)
Filter
Search Result
Results for "

labetuzumab govitecan

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    2
    TargetMol | All_Pathways
  • Inhibitory Antibodies
    1
    TargetMol | Inhibitory_Antibodies
  • PROTAC Products
    1
    TargetMol | PROTAC
  • ADC/ADC Related
    2
    TargetMol | All_Pathways
Labetuzumab govitecan
Labetuzumab-SN38, IMMU-130, IMMU130, IMMU 130, hMN14-SN38
T255931469876-18-3
Labetuzumab govitecan is an anti-CEACAM5/SN-38 antibody-drug conjugate for therapy of refractory or relapsing metastatic colorectal cancer.
  • $622
2-4 weeks
Size
QTY
CL2A
T177321846605-04-6
CL2A is a pH-sensitive, cleavable PEG8- and triazole-containing PABC-peptide-mc linker, characterized by its ability to induce a bystander effect. It forms a disulfide bond with an antibody at a cysteine residue. Labetuzumab govitecan utilizes this linker for its drug conjugation[1].
  • Inquiry Price
Inquiry
Size
QTY